Hypoglycaemia in patients with type 2 diabetes: minimising the risk

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 1, 2010, Pages 35-41

  Fisher, Miles ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Hypoglycaemia; Risk; Type 2 diabetes

Indexed keywords

CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

AGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEATH; DIARRHEA; DIET THERAPY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN RELEASE; MONOTHERAPY; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; SYMPTOM; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77952601722     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651409356092     Document Type: Review

References (54)

1. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Newer Agents. NICE short clinical guideline 87. London: National Institute for Health and Clinical Excellence, 2009.
2. Department of Health. QOF Changes and New Indicators for 2009/10. London: Department of Health, 2009.
3. Cryer PE. The barrier of hypoglycaemia in diabetes. Diabetes 2008;57:3169-3176
4. Wild D, von Maltzahn R, Brohan E et al. A critical review of the literature on fear of hypoglycaemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007;68: 10-15.
5. Frier BM. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes? Int J Clin Pract Suppl 2002;129:12-18.
6. Zammitt NN, Frier BM. Hypoglycaemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;12:2948-2961
7. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724-733
8. Spyer G, Hattersley AT, MacDonald IA et al. Hypoglycaemic counterregulation at normal blood glucose concentrations in patients with well-controlled type 2 diabetes. Lancet 2000;356:1970-1974
9. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-1912
10. Deary IJ, Hepburn DA, MacLeod KM, Frier BM. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993;36:771-777
11. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001;18:690-705.
12. Frier BM. Managing hypoglycaemia. Practitioner 2005;249:564-572
13. Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-1180
14. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-414
15. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-1147
16. National Diabetes Support Team. NDST Network Guide Supplement. Prevention of Type 2 Diabetes: Role of Diabetes Networks. London: NHS, 2007.
17. National Institute for Health and Clinical Excellence. NICE Implementation Uptake Report: Insulin Glargine for Diabetes (Types 1 and 2). London: National Institute for Health and Clinical Excellence, 2009.
18. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-254
19. Boyle PJ, Zrebiec J. Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. Diabetes Metab Res Rev 2008;24:257-285
20. Miller CD, Phillips LS, Ziemer DC et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-1659
21. United Kingdom Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
22. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulintreated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-1021
23. Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992;41:671-678
24. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycaemic coma in 102 diabetic patients. Arch Intern Med 1999;159:281-284
25. Leckie AM, Graham MK, Grant JB et al. Frequency, severity and morbidity of hypoglycaemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care 2005;28:1333-1338
26. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
27. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
28. Heller S. Minimizing hypoglycemia while maintaining glycemic control in diabetes. Diabetes 2008;57:3177-3183
29. Cefalu CA, Cefalu WT. Controlling hypoglycaemia in type 2 diabetes: which agent for which patient? J Fam Pract 2005;54:855-862
30. Browne DL, Avery L, Turner BC et al. What do patients with diabetes know about their tablets? Diabet Med 2000;17:528-531
31. Murata GH, Duckworth WC, Shah JH et al. Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Res Clin Pract 2004;65:61-67
32. Wright AD, Cull CA, Macleod KM et al. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications 2006;20:395-401.
33. Lewin A, Lipetz R, Wu J, Schwartz S. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. Clin Ther 2007;29:844-855
34. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-399
35. Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother 2008;42:1541-1551
36. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
37. Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
38. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
39. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348
40. Ahren B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 2007;30:1344-1350
41. Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab 2007;9:194-205.
42. Hermansen K, Kipnes M, Luo E et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with Type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-745
43. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568
44. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-166
45. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10: 82-90.
46. Rosenstock J, Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-185
47. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
48. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-1406
49. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycaemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955
50. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;CD005613.
51. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-189
52. Riddle MC, Rosenstock J, Gerich J et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
53. Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-259
54. Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-559